绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20211119003 | --- | --- | |---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20211102001 | --- | --- | --- | |-------------------------------|-------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20211109002 | --- | --- | --- | --- | |---------------------------|---------------|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------| | 证券简称：绿康生化 证券代码： | 002868 | 编号： 20211215005 | | | □特定对象调研 | □分析师会 ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20220210002 | --- | --- | --- | --- | --- | |--------------------|----------------------|------------------------------------------------------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20220209001 | --- | --- | --- | |-------------------------------|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

绿康生化股份有限公司 投资者关系活动记录表 证券简称：绿康生化 证券代码：002868 编号： 20220217003 | --- | --- | |-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's revenue for Q3 2022 was ¥89,802,349, representing a 14.68% increase compared to the same period last year[5]. - Total operating revenue for Q3 2022 was ¥234,068,484.09, a decrease of 7.5% compared to ¥252,150,180.35 in the same period last year[37]. - The net profit attributable to shareholders was -¥31,243,901.96, a decrease of 149.22% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥28,126,768.03, a decline of 539.52% compared to the previous year[5]. - Net loss for Q3 2022 was ¥68,093,068.62, compared to a net loss of ¥6,130,103.51 in Q3 2021, reflecting a significant decline in profitability[38]. - The total comprehensive income for the third quarter was -68,093,068.62 CNY, with a loss attributable to the parent company of -67,776,031.12 CNY[39]. - Basic and diluted earnings per share were both -0.44 CNY, compared to -0.04 CNY in the previous period[39]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,267,040,394.85, an increase of 0.69% from the end of the previous year[5]. - The company's total assets increased slightly to ¥1,267,040,394.85 from ¥1,258,398,896.70, showing stability in asset base despite losses[35]. - Total liabilities increased to ¥613,111,256.49 from ¥536,376,689.72, reflecting a growing debt burden[35]. - The company's cash and cash equivalents decreased from ¥97,495,450.53 to ¥34,717,251.56, indicating a liquidity challenge[34]. Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥13,515,864.69, a significant decrease of 4,342.38%[5]. - Cash inflow from operating activities totaled 302,118,093.41 CNY, an increase from 283,909,384.26 CNY in the previous period[42]. - The net cash flow from operating activities was -13,515,864.69 CNY, a significant decrease from 318,591.85 CNY in the previous period[42]. - Cash outflow from investing activities was 122,549,264.25 CNY, down from 242,961,229.25 CNY in the previous period[42]. - The net cash flow from financing activities was 69,264,478.11 CNY, compared to 164,938,738.37 CNY in the previous period[42]. - The ending balance of cash and cash equivalents was 34,717,251.56 CNY, down from 121,971,243.74 CNY in the previous period[42]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,457[16]. - Shanghai Kangyi Investment Co., Ltd. holds 30.43% of shares, totaling 47,291,400 shares, with 8,000,000 shares pledged[16]. - He Li (Asia) Investment Co., Ltd. holds 26.70% of shares, totaling 41,489,860 shares[16]. - The top ten shareholders include several domestic and foreign entities, with significant stakes held by Shanghai Kangyi and He Li Investment[17]. Investment and Acquisitions - The company plans to issue up to 46,624,751 shares in a non-public offering, which will not exceed 30% of the total share capital before the issuance[19]. - The total amount of funds to be raised from the non-public offering is expected to be no more than 305 million RMB[19]. - The acquisition of 100% equity in Jiangxi Wei Ke New Materials Technology Co., Ltd. is contingent upon the successful completion of the share transfer and asset sale[24]. - The deadline for the asset acquisition agreement has been extended to November 28, 2022, allowing for further negotiations[26]. - The company has suspended the share transfer and asset sale due to the need for further discussions among involved parties[25]. - The asset transfer is subject to audit and evaluation, with the transaction price yet to be determined, posing risks of termination if agreements cannot be reached[29]. - The asset acquisition agreement stipulates that if the transaction price is below 95 million yuan, the counterparty has the right to terminate the agreement[29]. Operational Challenges - The company's inventory increased by 72.52% to ¥105,587,860.43, indicating a rise in product stock at the end of the period[9]. - Accounts receivable increased to ¥55,386,102.48 from ¥44,031,827.95, suggesting potential issues with collections[34]. - Inventory levels rose significantly to ¥105,587,860.43 from ¥61,204,853.85, indicating potential overstocking or declining sales[34]. - The company reported a substantial increase in financial expenses, with interest expenses rising to ¥8,205,399.45 from ¥1,387,033.25[38]. - The company has not reported any net profit from mergers under common control, indicating no contribution from such activities[35]. Regulatory and Compliance - The non-public offering was approved by the China Securities Regulatory Commission (CSRC) on June 16, 2021[21]. - The approval for the non-public offering expired due to the inability to complete the issuance within 12 months, but it will not significantly impact the company's operations[22]. - The company has extended the validity period for the non-public offering resolution until February 18, 2023[21]. - The company has not yet issued a new notice for the shareholders' meeting regarding the share transfer, indicating significant uncertainty about approval[28]. - The implementation of the share transfer and asset sale is interdependent; failure of one will prevent the execution of the others[29]. - The company emphasizes the importance of timely information disclosure to investors regarding the progress of these transactions[26].

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 15%[18]. - The net profit attributable to shareholders for the same period was 80 million RMB, up 20% compared to the previous year[18]. - The company's revenue for the first half of 2022 was ¥144,266,135.09, a decrease of 17.01% compared to ¥173,844,094.41 in the same period last year[23]. - The net profit attributable to shareholders was -¥36,532,129.16, representing a decline of 656.46% from ¥6,565,087.10 in the previous year[23]. - The company reported a total profit of -43,463,603.44 CNY and a net profit attributable to shareholders of -36,532,129.16 CNY for the reporting period, primarily due to high costs associated with the veterinary drug investment project and the cogeneration project, as well as reduced sales revenue impacted by the Shanghai COVID-19 outbreak[47]. - The basic and diluted earnings per share were both -¥0.24, reflecting a decrease of 700.00% from ¥0.04 in the same period last year[23]. - The company reported a net loss for the first half of 2022 was CNY 36,658,331.41, compared to a net profit of CNY 6,485,648.32 in the first half of 2021[186]. - The total comprehensive loss for the first half of 2022 was CNY -36,658,331.41, compared to a comprehensive income of CNY 6,485,821.99 in the first half of 2021[186]. Market Expansion and Product Development - The company plans to launch two new products in Q4 2022, aiming to capture a larger market share in the biochemistry sector[18]. - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in sales in that region by the end of 2022[18]. - The company focuses on expanding its product structure and actively developing both domestic and international markets[38]. - The company plans to complete the annual production project of 1,200 tons of active bacterial peptide premix and 1,200 tons of veterinary raw materials by March 31, 2022[56]. - The company is actively pursuing an "internal + external" growth strategy to achieve sustainable development, focusing on the research and improvement of existing products and the registration of veterinary drugs to meet future market demands[48]. - Future guidance indicates a projected revenue growth of 10-15% for the second half of 2022[18]. Research and Development - Research and development expenses increased by 12%, reflecting the company's commitment to innovation and new technology[18]. - The company has accumulated 18 invention patents and 15 utility model patents, showcasing its commitment to innovation in the field of veterinary medicine[40]. - The company has allocated resources for research and development to enhance its product offerings and technological capabilities[197]. Financial Position and Cash Flow - The net cash flow from operating activities improved to ¥7,409,002.21, a significant increase of 140.37% compared to -¥18,353,447.83 in the same period last year[23]. - The company's total assets decreased by 1.49% to ¥1,239,692,295.94 from ¥1,258,398,896.70 at the end of the previous year[23]. - The net assets attributable to shareholders fell by 5.09% to ¥681,094,869.76 from ¥717,626,998.92 at the end of the previous year[23]. - Cash and cash equivalents decreased to ¥34,763,555.82, representing 2.80% of total assets, down from 7.75% in the previous year, a decrease of 4.95%[68]. - The company reported a significant increase in long-term equity investments to CNY 28,263,078.21 from CNY 34,713,691.52, indicating a decrease of approximately 18.7%[177]. - The total liabilities rose to CNY 554,328,420.37 from CNY 536,376,689.72, indicating an increase of about 3.6%[178]. Risk Management - The management highlighted potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[5]. - The company is addressing risks related to major customer procurement fluctuations by expanding its domestic market presence and developing new products[85]. - The company is actively managing environmental risks by implementing wastewater treatment and emissions monitoring systems[86]. - The company has approved a foreign exchange hedging business with a limit of up to $50 million to mitigate currency fluctuation risks[87]. Environmental and Social Responsibility - The company has established a wastewater treatment workshop at the Nanpu plant, with online monitoring of pollutants such as COD and ammonia nitrogen[100]. - The company has been actively promoting green development and has engaged in community tree planting activities to enhance ecological awareness[108]. - The company established a "Love Fund" to support 9 impoverished families with a total donation of 30,000 yuan in 2022, and has provided 6,000 yuan for the education of children of deceased employees[109]. - The company actively participated in poverty alleviation efforts, contributing a total of 40,000 yuan to support rural development in 2022[110]. Shareholder and Corporate Governance - The company held its first extraordinary shareholders' meeting on February 7, 2022, with a participation rate of 43.27%[91]. - The annual shareholders' meeting on May 18, 2022, had a participation rate of 71.90%[91]. - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[6]. - There were no changes in the company's board of directors, supervisors, or senior management during the reporting period[92]. - The company has no equity incentive plans or employee stock ownership plans in place[95]. Legal and Compliance Issues - The company is involved in litigation with a total amount of approximately 1,455.97 million yuan related to operational guarantees and interest payments[120]. - The company is also pursuing claims against Green Health Biochemical Co., Ltd. for a total of 2,607.31 million yuan, which includes compensation for equipment failures and economic losses[120]. - The company has not experienced any major litigation or arbitration matters during the reporting period[119].